

A STUDY ON THYROID PROFILE IN TYPE 2 DIABETES MELLITUS

Submitted to
The Tamil Nadu Dr. M.G.R. Medical University

**M.D. DEGREE EXAMINATION
BRANCH – I (GENERAL MEDICINE)**



**THE TAMIL NADU DR. M.G.R. MEDICAL
UNIVERSITY
CHENNAI**

MARCH 2010

BONAFIDE CERTIFICATE

This is to certify that "**A STUDY ON THYROID PROFILE IN TYPE 2 DIABETES MELLITUS**" is a bonafide work done by **Dr. SRIVIDYA. G**, post graduate student, Department of General Medicine, **K.A.P. VISWANATHAM GOVT. MEDICAL COLLEGE, TRICHY-1** under my guidance and supervision in partial fulfillment of regulations of **The Tamilnadu Dr. M.G.R. Medical University for the award of M.D. Degree Branch I, (General Medicine)** during the academic period from May 2008 to March 2011.

Prof. Dr.G.ANITHA M.D.,
Associate professor, unit-IV,
Dept of medicine,
K.A.P.V. Government Medical
College
Trichy -1

Prof. Dr. S.PANNEER SELVAM M.D.,
Professor and Head Of the Dept,
Dept of medicine, K.A.P.V. Government
Medical College
Trichy -1

DEAN
K.A.P.V. Government Medical College
Trichy -1

DECLARATION

I **Dr. Srividya. G** solemnly declare that the dissertation titled, **“A STUDY ON THYROID PROFILE IN TYPE 2 DIABETES MELLITUS”** is a bonafide work done by me at Annal Gandhi Memorial hospital affiliated to K.A.P.V. Government medical college, Trichy-1, during 2008-2010 under the guidance and supervision of **Prof Dr. S. PANNEER SELVAM, M.D.**, HOD/PROF of medicine and unit chief, **Prof Dr. G. ANITHA, M.D.**, The dissertation is submitted to **The Tamilnadu Dr.M.G.R.Medical University**, towards the partial fulfillment of requirement for the award of **M.D degree (Branch-I) in General Medicine.**

Place : Trichirappalli

Dr. Srividya .G

Date :

ACKNOWLEDGEMENT

It is with gratitude that I thank **Prof. Dr.S. PANNEER SELVAM M.D.,** Prof &Head of the Department of The Medicine for his constant guidance and encouragement he has given to me. I thank Professor **Dr.G. ANITHA, M.D.,** for her guidance is getting the best out of myself.

I thank Assistant professor **Dr.S. JOSEPH PANEERSELVAM D.DIAB, M.D.,** for his assistance throughout my work. I thank **Dr.N. Sundar M.D.,** and **Dr.K. Namasivayam, M.D.,** who have supported me in the work. I also thank college Dean who had shown keen interest in our academic activities. Finally I thank colleagues and patients who were involved in the study.

.

CONTENTS

SL. NO.	TITLE	PAGE NO.
1.	INTRODUCTION	1
2.	AIM	3
3.	REVIEW OF LITERATURE	4
4.	MATERIALS AND METHODS	25
5.	RESULTS AND ANALYSIS	30
6.	DISCUSSION	58
7.	SUMMARY	66
8.	CONCLUSION	68
	ANNEXURES BIBLIOGRAPHY PROFORMA MASTER CHART	

INTRODUCTION

INTRODUCTION

Diabetes mellitus is a common endocrine disorder which involves multiple organ systems and leads to significant morbidity and mortality due to accompanying complications. Diabetes mellitus has been defined as "A metabolic syndrome characterised by chronic hyperglycaemia and disturbance of carbohydrate, fat and protein metabolism associated with absolute or relative deficiency in insulin secretion and or insulin action".The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.

Much has been accomplished in the field of diabetes and what has been troubling everyone is the large macrovascular and micro vascular complications of diabetes involving kidneys, eyes, blood vessels, nerves and heart.

Thyroid diseases are also a common endocrinopathy seen in the adult population. Thyroid hormones are intimately involved in cellular metabolism.

Thus excess or deficit of either insulin or thyroid hormones could result in the functional derangement of the cellular metabolism.

The present work is a modest attempt to study the prevalence of thyroid disorders in patients with type 2 diabetes mellitus.

AIMS

AIM OF THE STUDY

1. To study the prevalence of thyroid disorders in patients with type 2 diabetes mellitus.
2. To study the distribution of thyroid disorders in patients with type 2 diabetes mellitus regarding age, sex, duration of diabetes, family history, regularity of treatment and BMI.
3. To evaluate the relationship between glycemic control and occurrence of altered thyroid function in type 2 diabetes mellitus.

REVIEW OF LITERATURE

REVIEW OF LITERATURE

Diabetes mellitus is characterised by chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both.¹

PROBLEM STATEMENT

In the first edition of the IDF Diabetes Atlas, released in 2000, the estimated global diabetes prevalence was 151 million. Now the estimated diabetes prevalence for 2010 has risen to 285 million, representing 6.4% of the world's adult population, with a prediction that by 2030 the number of people with diabetes will have risen to 438 million. Far from being a disease of higher income nations, diabetes is very much a disease associated with poverty and disproportionately affecting the lower socio-economic groups³. Although the prevalence of both type 1 and type 2 DM is increasing worldwide, the prevalence of type 2 DM is rising much more rapidly because of increasing obesity and reduced activity levels as countries become more industrialised. Previously a disease of the middle aged and elderly, type 2 diabetes has recently escalated in all age groups and is now being seen in younger age groups.⁴

Unfavourable modification of lifestyle and dietary habits with urbanisation are the most important factors for the development of diabetes. The percentage of diabetic cases in urban areas is projected to increase from 54% in 1995 to 73% by the year 2025.⁵ According to IDF (2009), India has the highest number of people suffering from diabetes mellitus with 50.8 million and spends 2.8 billionUS\$ or 1% of the global health expenditure for diabetes and related problems⁶. United Nations in 2006 in Resolution 61/225 stated that “diabetes is a chronic, debilitating and costly disease associated with severe complications, which poses severe risks for families, Member States and the entire world”.⁷

HISTORY

Diabetes is as old as medicine. Early evidence of description of symptoms of diabetes recorded in the Ebers papyrus, 1550 B.C.⁸ Arateus (30-90 AD), coined the term diabetes, meaning “siphon,” to explain the “liquefaction of the flesh and bones into urine”. In Greek this word means 'to run through' that describes 'unquenchable thirst' seen in association with this disease.⁹ Shushruta (Circa 600AD) noted this disease in Ayurveda and described it as "Madhumeha".¹⁰

In 1869, Paul Langerhans, published in his dissertation on pancreatic histology described “clumps of cells,” which were named the

islets of Langerhans shortly after his death.^{11,12} In 1889, Minkowski and Von Mering, in Strassburg, Germany, discovered the central role of the pancreas in diabetes.¹³ In 1910, Jean de Meyer suggested that the pancreatic secretion lacking in diabetic state to be called as “Insulin” to denote it’s origin from insulae of Langerhans.¹⁴ Banting and Charles Best in 1921, extracted insulin from dog's pancreas.¹⁵ The first chemical application of insulin was on 14 year old Leon and Thompson, a patient of diabetic ketoacidosis in January 1922 in Canada. This discovery revolutionized the management of diabetes. Oral hypoglycaemic drugs were introduced by Frank and Fuchs in 1955.⁸

DESCRIPTION OF DIABETES MELLITUS

When fully expressed, diabetes is characterized by fasting hyperglycemia, but the disease can also be recognized during less overt stages, most usually by the presence of glucose intolerance. Diabetes may present with characteristic symptoms such as thirst, polyuria, blurring of vision, weight loss and polyphagia. Hyperglycemia sufficient to cause pathologic functional changes may quite often be present for a long time before the diagnosis is made.¹ Patients may revert to having impaired glucose regulation or even normal glycemia, particularly in recent-onset type 2 diabetes.¹⁶

In type 1 diabetes, after a short period of insulin treatment, there may be a variable period when insulin is no longer required for survival and glucose tolerance may improve, the so-called honeymoon period. Eventually such patients do need insulin treatment for survival.¹⁷

Etiologic Classification of diabetes mellitus²

I. Type 1 diabetes

A. Immune mediated

B. Idiopathic

II. Type 2 diabetes

III. Other specific types

A. Genetic defects of β - cell function

B. Genetic defects in insulin action

C. Diseases of the exocrine pancreas

D. Endocrinopathies

E. Drug - or chemical induced

F. Infections

G. Uncommon forms of immune-mediated diabetes

H. Other genetic syndromes sometimes associated with diabetes

IV. Gestational diabetes mellitus (GDM)

The majority of cases of diabetes fall into two broad etiopathogenetic categories, now called type 1 and type 2 diabetes.

TYPE 1 DIABETES MELLITUS

Type 1 diabetes is the form of the disease due primarily to β -cell destruction in which insulin is required for survival. It is characterized by the presence of anti-GAD, anti-islet cell, or antiinsulin antibodies, which reflects the autoimmune processes that have led to β -cell destruction.^{18,19}

TYPE 2 DIABETES MELLITUS

Type 2 diabetes is the most common form of diabetes. Insulin resistance and abnormal insulin secretion are central to the development of type 2 DM.² Patients with type 2 diabetes usually have insulin resistance and relative, rather than absolute, insulin deficiency and are associated with progressive β -cell failure with increasing duration of diabetes.²⁰ The risk of developing type 2 diabetes increases with age, obesity, physical inactivity and family history of diabetes.¹ The disease can occur at any age and is now seen in children and adolescents.²¹

DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS²²

Symptoms of diabetes plus random plasma glucose concentration 200 mg/dl (11.1 mmol/l). Random is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia and unexplained weight loss (or)

FPG 26 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 hours. (or)

2 hours post load glucose 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by WHO, using a glucose load containing the equivalent of 75 gm anhydrous glucose dissolved in water.

In the absence of unequivocal hyperglycaemia these criteria should be confirmed by repeat testing on a different day. FPG is the most reliable and convenient test for identifying DM in asymptomatic individuals. HbA1C is not currently recommended to diagnosis of diabetes.

IMPAIRED GLUCOSE TOLERANCE¹

Defined as 2 hours values in the oral glucose tolerance test (OGTT) between 140 and 199mg/dl (7.8 and 11.1 mmol/L). Glucose tolerance is above the conventional normal range but lower than the level diagnostic of diabetes. Persons with IGT have a high risk of developing diabetes and

arterial disease. IGT is more frequent in obese persons and often is associated with hyperinsulinemia and insulin resistance.

IMPAIRED FASTING GLUCOSE¹

Defined as fasting plasma glucose concentrations of 100 to 125 mg/dL (5.6 to <7.0 mmol/L). IFG is also a stage of impaired glucose homeostasis with fasting glucose levels were above normal but below those diagnostic for diabetes.

ACUTE COMPLICATIONS OF DM²

Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are acute complications of diabetes. DKA primarily occurs in type 1 DM but, can also occur in type 2 DM. HHS is primarily seen in individuals with type 2 DM. Both disorders are associated with absolute or relative insulin deficiency, volume depletion, and acid-base abnormalities.

CHRONIC COMPLICATIONS OF DM²

The vascular complications of DM are divided into microvascular (retinopathy, neuropathy, nephropathy) and macrovascular complications [coronary artery disease (CAD), peripheral arterial disease (PAD), cerebrovascular disease]. Nonvascular complications include problems

such as gastroparesis, infections, and skin changes. The microvascular complications of both type 1 and type 2 DM result from chronic hyperglycemia. Evidence implicating a causative role for chronic hyperglycemia in the development of macrovascular complications were inconclusive. Other factors (dyslipidemia and hypertension) also play important roles in macrovascular complications.

DYSLIPIDEMIA IN DIABETES

The dyslipidemia in type 2 diabetes and insulin resistance typically consists of elevated triglycerides and decreased HDL cholesterol level²³ and of qualitative abnormality in the LDL structure, i.e., decreased size and increased density of the LDL particle.

METABOLIC SYNDROME AND OBESITY²⁵

The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of a constellation of metabolic abnormalities that confer increased risk of cardiovascular disease (CVD) and diabetes mellitus (DM). Diagnosis of the metabolic syndrome requires the presence of at least three of the following five criteria²⁶

1. Elevated fasting plasma glucose levels (>110 mg/dL)
2. Visceral obesity (waist circumference >35 inches in women and 40 inches in men)

3. Hypertension (>130/85 mm Hg)
4. Hypertriglyceridemia (>150 mg/dL)
5. Low high-density lipoprotein (HDL) cholesterol (<40 mg/dL in men and <50 mg/dL in women)

THYROID

The thyroid (Greek thyreos, shield, plus eidos, form) consists of two lobes that are connected by an isthmus. It is located anterior to the trachea between the cricoid cartilage and the suprasternal notch. Four parathyroid glands, which produce parathyroid hormone are located posterior to each pole of the thyroid.²⁷

The normal thyroid gland secretes sufficient amounts of the thyroid hormones triiodothyronine (T3) and tetraiodothyronine (T4, thyroxine) to normalize growth and development, body temperature, and energy levels. Calcitonin, the second type of thyroid hormone, is important in the regulation of calcium metabolism.²⁸

BIOSYNTHESIS OF THYROID HORMONES²⁷

Iodide, ingested from food, water, or medication, is rapidly absorbed from intestine and enters an extracellular fluid pool. Transport of iodide into the thyroid gland is by an intrinsic follicle cell basement

membrane sodium/iodide symporter (NIS). At the apical cell membrane a second I- transport enzyme called pendrin is present. Iodide is oxidized by thyroidal peroxidase to iodine that rapidly iodinates tyrosine residues within the thyroglobulin molecule to form moniodotyrosine (MIT) and diiodotyrosine (DIT). This process is called iodide organification. Two molecules of DIT combine within the thyroglobulin molecule to form L-thyroxine (T4). One molecule of MIT and one molecule of DIT combine to form T3. T4, T3, MIT, and DIT are released from thyroglobulin by exocytosis and proteolysis of thyroglobulin at the apical colloid border. Most of the hormone released is thyroxine. Most of the T3 circulating in the blood is derived from peripheral metabolism of T4.

Both hormones are bound to plasma proteins, including thyroxine binding globulin (TBG); transthyretin (TTR); and albumin. The plasma binding proteins increase the pool of circulating hormone, delay hormone clearance, and may modulate hormone delivery to selected tissue sites.

DEIODINASES²⁷

T4 is converted to T3 by the deiodinase enzyme.

- ¶ Type I deiodinase, which is located primarily in thyroid, liver, and kidney, has a relatively low affinity for T4.

¶ Type II deiodinase has a higher affinity for T₄ and is found primarily in the pituitary gland, brain, brown fat, and thyroid gland.

¶ Type III deiodinase inactivates T₄ and T₃ and is the most important source of reverse T₃ (r T₃)

PHYSIOLOGICAL EFFECTS OF THYROID HORMONES²⁹

- ^a Heart: Increases number of β adrenergic receptors. Enhances response to catecholamines
- ^a Adipose tissue: Stimulate lipolysis
- ^a Muscle: Increases protein breakdown
- ^a Bone: Promote growth and development
- ^a Nervous system: Promote normal brain development
- ^a Gut: Increases carbohydrate absorption
- ^a Lipoprotein: Stimulate LDL receptors
- ^a Others: Increases metabolic rate and oxygen consumption

REGULATION OF THYROID AXIS²⁷

The thyroid axis is a classic example of an endocrine feedback loop. TRH stimulates pituitary production of TSH, which, in turn, stimulates thyroid hormone synthesis and secretion. Thyroid hormones feed back to inhibit TRH and TSH production.

EXOGENOUS AND ENDOGENOUS FACTORS SUPPRESSING TSH SECRETION³⁰

Dopamine antagonists, Somatostatin, Dobutamine, Glucocorticoids, Interleukins, TNF- α , Thyroid hormones and Phenytoin.

FACTORS ASSOCIATED WITH ALTERED BINDING OF THYROXINE BY THYROXINE-BINDING GLOBULIN³⁰

Increased Binding

Pregnancy, Oral contraceptives, Infectious hepatitis, Cirrhosis, HIV, Acute intermittent porphyria and Tamoxifen.

Decreased Binding

Androgens, Large doses of glucocorticoids, acromegaly, Nephrotic syndrome, Major systemic illness and Psychiatric illness.

FACTORS ASSOCIATED WITH DECREASED CONVERSION OF T4 TO T3³⁰

Fetal life, Caloric restriction, Hepatic disease, Major Systemic illness, Propylthiouracil, Glucocorticoids, Propranolol, Iodinated X-ray contrast agents, Amiodarone and Selenium deficiency.

HYPOTHYROIDISM

Hypothyroidism is the condition resulting from a lack of effects of thyroid hormones on body tissues.³¹

Symptoms

Tiredness, weakness, dry skin, feeling cold, hair loss, difficulty concentrating and poor memory, constipation, weight gain with poor appetite, dyspnea, hoarse voice, menorrhagia (later oligomenorrhea or amenorrhea), paresthesia and impaired hearing.

Signs

Dry coarse skin; cool peripheral extremity, puffy face, hands, and feet (myxedema), diffuse alopecia, bradycardia, peripheral edema, delayed tendon reflex relaxation, carpal tunnel syndrome and serous cavity effusions²⁷

METABOLIC ABNORMALITIES IN HYPOTHYROIDISM

Hypothyroidism is associated with a reduction in glucose disposal to skeletal muscle and adipose tissue and also associated with reduced gluconeogenesis. The net effect of these influences is usually minimal on serum glucose levels. Degradation of insulin, is slowed and the sensitivity to exogenous insulin may be increased.³² Both the synthesis and the degradation of lipid are depressed in hypothyroidism with a net effect of accumulation of LDL and triglycerides. HDL concentrations and Plasma free fatty acid levels are decreased.³³

SUBCLINICAL HYPOTHYROIDISM

Defined as a low-normal free T4 but a slightly elevated serum TSH level. The TSH elevation in such patients is modest, with values typically between 4 and 15 mU/L.³³ Rates of progression to overt hypothyroidism ranges from 3% to 8% per year, higher rates seen in individuals with initial TSH concentration greater than 10 mU/L and those with positive anti-TPO antibodies.³⁴ The association of mild hypothyroidism with an increase in risk for atherosclerotic heart disease has been shown by some, but not others.^{35,36}

HYPERTHYROIDISM²⁷

Hyperthyroidism is a state when thyrotoxicosis occurs because of sustained over production of hormones by thyroid gland.

Symptoms

Heat intolerance and sweating, palpitation, fatigue and weakness, weight loss with increased appetite, diarrhea, polyuria, oligomenorrhea, and loss of libido.

Signs

Tachycardia; atrial fibrillation in the elderly, tremor, goiter, warm, moist skin, muscle weakness, proximal myopathy, lid retraction or lag and gynecomastia.

METABOLIC ABNORMALITIES IN HYPERTHYROIDISM

Preexisting diabetes mellitus may be aggravated, one cause being accelerated turnover of insulin.³⁷ Both lipogenesis and lipolysis are increased in thyrotoxicosis, but the net effect is lipolysis, as reflected by an increase in the plasma concentration of free fatty acids and glycerol and a decrease in serum cholesterol level. Triglyceride levels are usually slightly decreased.³⁸

SUBCLINICAL HYPERTHYROIDISM

There are no signs of thyrotoxicosis but the serum TSH is subnormal despite normal serum free T4 concentration.³⁷ Subclinical hyperthyroidism may accelerate bone loss in postmenopausal women³⁹ and increases the incidence of atrial arrhythmias including atrial fibrillation in elderly patients.³¹

DIABETES AND THYROID DISEASES

Diabetes mellitus and thyroid diseases are the two common endocrinopathies seen in the adult population. Insulin and thyroid hormones are intimately involved in cellular metabolism. Excess or deficit of either of these hormones could result in the functional derangement of the other.⁴⁰

EFFECT OF DIABETES ON THYROID FUNCTION

In euthyroid individuals with diabetes mellitus, the serum T3 levels, basal TSH levels and TSH response to thyrotropin releasing hormone (TRH) may all be strongly influenced by the glycemic status.⁴¹ Poorly controlled diabetes, both Type 1 and Type 2, may induce a “Low T3 state” characterized by low serum total and free T3 levels, increase in reverse T3 (r T3) but near normal serum T4 and TSH concentrations.⁴² Low serum T3 is due to reduced peripheral conversion of thyroxine (T4) to tri-iodothyronine (T3) via 5’ monodeiodination reaction and may normalize with improvement in glycemic status but even with good diabetes control, the normal nocturnal TSH peak may not be restored in C-peptide negative patients.⁴³

EFFECT OF DIABETES MELLITUS ON THYROID DISEASES

Dysthyroid optic neuropathy (DON) resulting in blindness is the most threatening complication of Graves’ orbitopathy (GO). It is due to the compression of optic nerve by enlarged extraocular muscles at the orbital apex.

Incidence of DON in patients with diabetes mellitus is higher than that seen in control “GO” group and the recovery after treatment is also poor. This has been explained by reduced oxygenation of optic nerve in

diabetic patient owing to the vasculopathy making it more susceptible to the pressure effect.⁴⁴

EFFECT OF HYPERTHYROIDISM ON GLYCEMIC STATUS

Graves disease is the commonest cause of hyperthyroidism. While Graves disease may be associated with type 1 diabetes in polyglandular autoimmune syndrome, thyrotoxicosis by itself is diabetogenic. Frank diabetes occurs in 2-3%, when hyperthyroidism develops in normal individuals. In known diabetic patients hyperthyroidism causes deterioration of glycemic control status.⁴²

These changes are due to alteration in following systems

1. Gastrointestinal System

In hyperthyroidism, there is accelerated gastric emptying, enhanced intestinal glucose absorption and an increase in portal venous blood flow.⁴⁴

2. Insulin Secretion

Insulin secretion decreases in hyperthyroidism.^{45,46} Insulin clearance rate is reported to be increased by about 40%.⁴⁷ Long term thyrotoxicosis has been shown to cause beta cell dysfunction resulting in poor insulin response to glucose.⁴⁸

3. Endogenous Glucose Production

In hyperthyroidism the endogenous glucose production is greatly increased by a variety of mechanisms: (a) there is an increase in the availability of gluconeogenic precursors(lactate, glutamine, alanine and FFA) stimulating hepatic gluconeogenesis;⁴⁹ (b) Inhibition of glycogen synthesis;⁵⁰ (c) Upregulation of GLUT-2 glucose transporters protein expression in the hepatocyte;⁵¹ (d) Increased secretion and exaggerated effects of glucagon and adrenaline on liver cells.⁴⁹

4. Glucose utilization

In adipocytes isolated from rats, the sensitivity of glucose transport and utilization to insulin has been found to be normal, increased or decreased.⁴⁵ In skeletal muscle, there is a preferential increase in glucose uptake and lactate formation . This is due to increase in GLUT-1 and GLUT-4 transporters⁵², increased glycogenolysis due to beta adrenergic stimulation⁴⁹, increased activity of hexokinase and 5 phosphofructokinase.⁵³

Thus the net effect of changes occurring at various levels such as gastrointestinal tract, beta cells, hepatocytes, adipocytes and skeletal muscles is hyperglycemia.

EFFECT OF HYPOTHYROIDISM ON GLYCEMIC STATUS

In hypothyroidism, the synthesis and release of insulin is decreased.⁴⁶ The rate of hepatic glucose output is decreased probably due to reduced gluconeogenesis. A post receptor defect has been proposed to explain the decrease in insulin stimulated glucose utilization in peripheral tissues.⁴⁹ The net effect is an increased risk of recurrent hypoglycemia in a diabetic individual.⁵⁴

ASSOCIATION BETWEEN DIABETES MELLITUS AND THYROID DISORDERS

Celani MF et al in their study found that abnormal TSH values in type 2 diabetic patients found before tight glycemic control reverted to normal values with adequate treatment of diabetes with OHA or insulin. They suggested that the diagnosis of thyroid dysfunction in type 2 diabetes should be delayed until improvement of metabolic status.⁵⁵

Proces S et al in their study found that in diabetic patients TSH was lower than in non diabetic subjects. They concluded that besides known parameters such as age and drugs, thyroid function tests can also be altered in diabetes mellitus and obesity.⁵⁶

Warren RE et al in their study found that serum thyrotropin (i.e. baseline TSH) is a better predictor of thyroid dysfunction than thyroid autoantibodies in people with diabetes.⁵⁷

Vondra K et al in their study found that prevalence of thyroid disease in diabetic patients is 2-3 times higher than in non diabetic subjects. It raises with age and is strongly influenced by female gender and autoimmune diabetes. They even recommended thyroid disease screening and diagnosis in patients with diabetes mellitus.⁵⁸

Abdel Rahman et al in their study found that overall prevalence of thyroid diseases was 12.5% in type 2 diabetes mellitus group. The study suggested that diabetic patients should be screened for asymptomatic thyroid dysfunction.⁵⁹

Perros P et al in their study found that the prevalence of thyroid disease was 13.4% in a randomly selected group of 1310 adult diabetic patients attending a diabetic clinic. They suggested that thyroid function should be screened annually in diabetic patients to detect asymptomatic thyroid dysfunction which is increased in frequency in a diabetic population.⁶⁰

Smithson MJ in his study found that the prevalence of thyroid disease (previously known and diagnosed as a result of screening) in the entire population of diabetic patients in his sample of 4300 general

practice patients was 10.8%. He concluded by suggesting that screening for thyroid disease should be considered in patients receiving diabetes care in community.⁶¹

Zdrojewicz Z et al in their study found that there was no difference in thyroid gland function in patients with non insulin dependent diabetes mellitus (type 2) and different therapies have no influence on thyroid gland function.⁶²

Parr JH et al in their study found that improvement in long term metabolic control did not influence free thyroid hormone levels in well controlled and moderately-poor controlled diabetics taking insulin.⁶³

Chubb SA et al in their study found that none of those patients with type 2 diabetes diagnosed as subclinical hypothyroidism had overt hypothyroidism when restudied after 5 years. So they concluded that subclinical hypothyroidism is a common but incidental finding and routine screening of thyroid function in type 2 diabetes is questionable.⁶⁴

MATERIALS AND METHODS

MATERIALS AND METHODS

The present study titled "Thyroid Profile in Type 2 Diabetes Mellitus" was carried out in the Department of Medicine and in the Department of Diabetology, AGMGH, Trichy.

- Study design: Cross sectional study.
- Period of study: January 2010 to October 2010
- Materials: Questionnaire, BMI calculation, Blood pressure, FBS, PPBS, Blood Urea, Serum creatinine, ECG, Thyroid profile (FT3, FT4 and TSH)
- Study group: The study group included 100 persons with known type 2 diabetes without known thyroid disorders attending the outpatient departments who met the inclusion criteria.

Inclusion Criteria

Known type 2 diabetes mellitus subjects who gave informed consent to participate in the study.

Exclusion Criteria

- E** Patients not willing for study
- E** Patients with known thyroid disease
- E** Patients with chronic renal failure and Diabetic nephropathy.

E Patients with acute illness (sepsis, acute MI, severe heart failure, recent admission in intensive care unit)

E Patients with hepatic dysfunction

E Patients with psychiatric illness.

E Pregnancy

E Patients on treatment with drugs interfering with thyroid function (amiodarone, propranolol, corticosteroids and oral contraceptives)

All patients in the study group were selected without any bias for sex, duration, severity or control of diabetes. A thorough history was recorded with particular emphasis on symptoms of hypothyroidism and hyperthyroidism. The presence of associated illness like coronary artery disease, hypertension and cerebrovascular accident were noted. Family history regarding diabetes mellitus and treatment history of oral hypoglycaemics or insulin along with duration was also included.

A thorough general and systemic examination was carried.

BMI calculation

Body mass index (BMI) is calculated with height and weight of the subject using the following formula.

$$\text{BMI} = \frac{\text{weight(kg)}}{\text{height(m}^2\text{)}}$$

Blood sugar

Both fasting and postprandial blood sugar are estimated by Trinder's (Glucose oxidase) method and read at 505/670 nm.

Renal function test

The Blood Urea in this study was estimated using DAM method (Diacetyl Monoxime). Serum creatinine was estimated using Modified Jaffe's method.

Thyroid Profile

Estimation done in fasting serum sample.

Methods used:

1. TSH - Ultrasensitive sandwich chemi luminescent immuno assay
2. FT3 & FT4 - Competitive chemi luminescent immuno assay.

DEFINITIONS

Diabetes Mellitus

The WHO in consultation with an expert committee of the American Diabetes Association has approved the following diagnostic criteria for Diabetes Mellitus, which was used to diagnose new cases. The

patients on antidiabetic therapy were also considered as having diabetes mellitus.

Fasting: No caloric intake for atleast 8 hours.2-3 days of unrestricted carbohydrate diet prior to the test. No physical activities during the procedures.

Systemic Hypertension (As per the JNC VII Guidelines): Subjects on medications for hypertension and those who had a systolic blood pressure of 140 mmHg and / or diastolic blood pressure 90 mmHg were considered to have hypertension.

Diabetes mellitus is considered as Coronary Heart Disease equivalent.

BMI (WHO criteria for Asian population): is used for classifying the subjects according to the weight status.

BMI Group	BMI (kg/m²)
Underweight	< 18.5
Normal weight	18.5-24.9
Overweight	25-29.9
Obesity	30.0

Thyroid profile

Reference values: FT3 : 1.7-4.2 pg/ml

FT4: 0.7- 1.8 ng/dl

TSH: 0.35-5.5 µIU/ml

- ✓ Overt hypothyroidism is defined as $\text{TSH} > 5.5 \mu\text{IU/ml}$ with $\text{FT4} < 0.7 \text{ ng/dl}$.
- ✓ Subclinical hypothyroidism is defined as $\text{TSH} > 5 \mu\text{IU/ml}$ with normal FT3 and FT4 levels
- ✓ Overt hyperthyroidism is defined as $\text{TSH} < 0.3 \mu\text{IU/ml}$ with $\text{FT4} > 1.8 \text{ ng/dl}$
- ✓ Subclinical hyperthyroidism is defined as $\text{TSH} < 0.3 \mu\text{IU/ml}$ with normal FT3 and FT4 levels

RESULTS AND ANALYSIS

RESULTS AND ANALYSIS

The present study titled “Thyroid Profile in Type 2 Diabetes Mellitus” was undertaken in the Department of Medicine and Department of Diabetology, AGMGH, trichy over a period of 10 months from January 2010 to October 2010.

The study sample included 100 type 2 diabetes patients in the outpatient department. Following were the observations:

Table-1
Age Distribution of Cases

Age Group (yrs)	No. of cases	Percentage
Upto 40	24	24
41-60	58	58
61 & above	18	18
Total	100	100.0

Age Distribution of Cases




Table-2
Distribution of Cases According to Sex

Sex	No. of cases	Percentage
Male	52	52
Female	48	48
Total	100	100.0

Distribution of Cases According to Sex




Table -3
Distribution According to Duration of Diabetes Mellitus

Duration of DM	No. of cases	Percentage
Upto 5 Years	74	74
6 – 10 Years	20	20
More than 10 Years	6	6
Total	100	100

Distribution According to Duration of Diabetes Mellitus




Table-4
Distribution According to Regularity of treatment

Regularity of Treatment	No. of cases	Percentage
Regular	82	82
Irregular	18	18
Total	100	100.0

Distribution According to Regularity of treatment




Table – 5
Distribution according to Family history of Diabetes Mellitus

Family H/O DM	No. of cases	Percentage
Yes	44	44
No	56	56
Total	100	100.0

Distribution according to Family history of Diabetes Mellitus




Table-6
Distribution of cases according to BMI

BMI Group (Kg/m²)	No. of cases	Percentage
< 18.5	2	2
18.5-24.9	18	18
25 – 29.9	56	56
Above 30	24	24
Total	100	100.0

Among the study population, 80% (80/100) were overweight and obese; 18% (18/100) had normal BMI.

Distribution of cases according to BMI




Table-7

Distribution of Cases according to Abnormal thyroid profile

Thyroid Function	Number	Percentage
With normal thyroid profile	80	80
With abnormal thyroid profile	20	20
Total	100	100.0

Distribution of Cases according to Abnormal thyroid profile





Table – 8
Distribution of thyroid diseases

Thyroid Profile	No. of cases	Percentage
Normal	80	80
Overt hypothyroidism	3	3
Subclinical hypothyroidism	11	11
Over hyperthyroidism	1	1
Subclinical hyper thyroidism	5	5
Total	100	100.0

The above table shows that 11% (11/100) of the patients had report suggestive of sub clinical hypothyroidism and 5% (5/100) of the patients had report suggestive of sub clinical hyperthyroidism.

Distribution of thyroid diseases



DISTRIBUTION OF THYROID DISEASE IN THE POPULATION STUDIED

NO	NAME	AGE/SEX YEARS	FT3 rg/ml	FT4 hg/dl	TSH mIU/ml	DIAGNOSIS
1	Mr. Palanisamy	60/M	3.2	1.4	7.92	Subclinical hypothyroidism
2	Mrs. Vasanthakumari	40/F	2.72	0.86	6.24	Subclinical hypothyroidism
3	Mrs. Rajalakshmi	57/F	2.57	0.86	5.924	Subclinical hypothyroidism
4	Mrs. Maanvizhi	46/F	2.81	1.2	5.938	Subclinical hypothyroidism
5	Mr. Periyasamy	72/M	2.18	1.05	9.696	Subclinical hypothyroidism
6	Mr. Annadurai	36/M	2.99	1.07	6.139	Subclinical hypothyroidism
7	Mr. Kumar	53/M	2.69	0.85	9.611	Subclinical hypothyroidism
8	Mrs. Shanmugarani	52/F	2.61	1.0	5.671	Subclinical hypothyroidism
9	Mr.Maniyan	59/M	3.15	1.1	6.434	Subclinical hypothyroidism
10	Mrs.Velmani	45/F	2.6	0.88	8.9	Subclinical hypothyroidism
11	Mrs.Amsavalli	42/F	2.79	0.65	9.8	Subclinical hypothyroidism
12	Mrs.Dhanushkodi	50/F	2.59	0.63	38.43	Overt hypothyroidism
13	Mrs.Meenambigai	42/F	1.5	0.46	> 150	Overt hypothyroidism
14	Mrs.Pushpa	56/F	2.33	0.71	35.64	Overt hypothyroidism
15	Mrs.Tamilarasi	40/F	3.2	1.88	0.28	Subclinical hyperthyroidism
16	Mrs.Uma maheswari	40/F	3.62	1.8	<0.01	Subclinical hyperthyroidism
17	Mrs.Jaya	39/F	3.17	1.3	0.205	Subclinical hyperthyroidism
18	Mrs.Suganthi	37/F	2.66	1.11	0.21	Subclinical hyperthyroidism
19	Mrs.Latha	35/F	3.03	1.32	0.172	Subclinical hyperthyroidism
20	Mr.Gunasekaran	40/M	8.41	4.72	0.015	Overt hyperthyroidism

Table – 9
Abnormal thyroid profile Vs Age group

Agegroup(yrs)	Abnormal thyroid profile			
		No	Yes	Total
Up to 40	count	16	8	24
	% with abnormal thyroid profile	20	40	
	% of total	16	8	24
41-60	count	47	11	58
	% with abnormal thyroid profile	58.75	55	
	% of total	47	11	58
>60	count	17	1	18
	% with abnormal thyroid profile	21.25	5	
	% of total	17	1	18
Total	count	80	20	100
	% with abnormal thyroid profile	100	100	
	% of total	80	20	100

P> 0.05 Not significant

Out of 20 patients with abnormal thyroid profile, 1patient (5%) were found to be of age 61years and more, 11 (55%) were found to be of age between 41-60 years and 8 (40%) were found to be 40 years or less.

Compared with normal thyroid profile group it has no statistical significance.

Abnormal thyroid profile Vs Age group




Table-10
Abnormal thyroid profile Vs Sex

Sex	Abnormal thyroid profile			
		No	Yes	Total
Male	count	46	6	52
	% with abnormal thyroid profile	57.5	30	
	% of total	46	6	52
Female	count	34	14	48
	% with abnormal thyroid profile	42.5	70	
	% of total	34	14	48
Total	count	80	20	100
	% with abnormal thyroid profile	100	100	
	% of total	80	20	100

P <0.05 Significant

Out of 20 patients with abnormal thyroid profile, 30%(6) were males and 70%(14) were females. Compared with normal thyroid profile group, this is statistically significant .

Abnormal thyroid profile Vs Sex




Table-11**Abnormal thyroid profile Vs Duration of Diabetes**

Duration (yrs)	Abnormal thyroid profile			
		No	Yes	Total
Up to 5	count	58	16	74
	% with abnormal thyroid profile	72.5	80	
	% of total	58	16	74
6-10	count	17	3	20
	% with abnormal thyroid profile	21.25	15	
	% of total	17	3	20
>10	count	5	1	6
	% with abnormal thyroid profile	6.25	5	
	% of total	5	1	6
Total	count	80	20	100
	% with abnormal thyroid profile	100	100	
	% of total	80	20	100

p>0.05 not Significant

Among the 20 patients with abnormal thyroid profile, 5%(1) had Diabetes more than 10 years, 15%(3) had duration between 6-10 years and 80%(16) had Diabetes 5 years or less. It is not statistically significant.

Abnormal thyroid profile Vs Duration of Diabetes




Table-12
Abnormal thyroid profile Vs Family history of Diabetes

Family history of DM	Abnormal thyroid profile			
		No	Yes	Total
YES	count	26	18	44
	% with abnormal thyroid profile	32.5	90	
	% of total	26	18	44
NO	count	54	2	56
	% with abnormal thyroid profile	67.5	10	
	% of total	54	2	44
Total	count	80	20	100
	% with abnormal thyroid profile	100	100	
	% of total	80	20	100

$P < 0.05$ Significant

18 (90%) out of 20 patients with thyroid abnormality had family history of diabetes, but only 32.5%(26) of normal thyroid group had it. Statistically the difference is significant.

Abnormal thyroid profile Vs Family history of Diabetes




Table-13


Abnormal Thyroid Profile Vs BMI

BMI	Abnormal thyroid profile			
		Yes	No	Percentage
<18.5	count	1	1	
	% of total	5	5	5
18.5-24.9	count	4	14	
	% of total	20	17.5	20
25-29.9	count	9	47	
	% of total	45	58.75	45
>30	count	6	18	
	% of total	30	22.5	30

p >0.05 Not significant

Out of 20 persons with abnormal thyroid profile, 75%(15) were overweight and obese. Compared with normal thyroid profile group this is not statistically significant.

Distribution of Abnormal thyroid profile according to BMI



DISCUSSION

DISCUSSION

Diabetes mellitus is the most common endocrine disorder which involves multiple organ systems and leads to significant morbidity and mortality due to accompanying complications. Thyroid diseases are also a common endocrinopathy seen in the adult population. Thyroid hormones are intimately involved in cellular metabolism. Thus excess or deficit of either insulin or thyroid hormone could result in the functional derangement of the cellular metabolism.

In the present study patients of diabetes mellitus were taken from Diabetic Outpatient Department, AGMGH, Trichy, over a period of 10 months from January 2010 to October 2010 and they were evaluated for altered thyroid profile.

AGE DISTRIBUTION

In the present study of 100 type 2 diabetic patients, 24 patients (24%) were up to 40 years, 58 patients (58%) were between 41-60 years and 18 patients (18%) were 61 years or more. This shows that the disease was more prevalent between 41-60 years of age.

This observation was similar to WHO report which predicts that while the main increase in diabetes would be in the > 65 year age group

in the developed countries, in India and developing countries the highest increase would occur in the age group of 45-65 year of age group.⁶⁵

This observation is also similar to Kapur et al, who reported that maximum number of cases were diagnosed between 40 and 59 year of age with no significant difference between the genders.⁶⁶

GENDER DISTRIBUTION

In the present study 52% (52 nos) of the studied population were males and 48% (48 nos) were females. Male to Female ratio was 1.08:1.

This observation was similar to Jali et al⁶⁸ and Flatau E et al⁶⁹ who reported that diabetes was more prevalent in men than in women.

This is in contrast to Arthur M. Michalek et al who reported that prevalence of diabetes among women was higher than in men.⁶⁷ Sample size in our study is too small. This might have affected the results.

DURATION OF DIABETES MELLITUS

In the present study, majority of cases that is 74% (74/100) had duration of diabetes up to 5 years, 20% (20/100) of patients had duration between 6-10 years and 6% (6/100) of patients had duration of illness more than 10 years. Majority of people are in the age group between 41 to 60 yrs and have duration of disease less than 5 years.

FAMILY HISTORY OF DIABETES MELLITUS

In the present study, 44% (44nos) of patients had family history of diabetes and the remaining 56% (56nos) had no family history.

This study is similar to that of Tattersal and Fojans⁷⁰ and Vishwanthan.⁷¹ Vishwanthan et al conducted a study among 107 subjects. Out of 73 subjects who gave positive family history diabetes, 19 subjects (26%) later developed diabetes.

REGULARITY OF TREATMENT

In the present study, out of 100 subjects of the study group 82% (82/100) were on regular treatment and 18% (18/100) were irregular.

Asha et al observed that 97% of type 2 diabetics were on antidiabetic agents and most were using them irregularly.⁷²

Kaur et al observed that oral anti diabetic drug compliance rate was 62.9% in diabetic population.⁷³ The difference in our study may be due to small sample size.

BMI

Among the study population, 80%(80/100) were overweight and obese; 18%(18/100) had normal BMI. Mc Larty et al reported that prevalence of IGT in subjects of all age group increased with rising BMI.⁷⁴

Yon Gik et al reported that the prevalence of diabetes mellitus and IGT increased with rising BMI and with increase in WHR.⁷⁵ Both these studies support our findings.

ABNORMAL THYROID PROFILE

In the present study, 20% (20) of the total 100 patients with diabetes mellitus had abnormal thyroid profile. The present study is similar to Abdel-Rahman et al who in his study of 908 type 2 diabetic patients found that the prevalence of thyroid disease was 12.5%, 6.6% of whom were newly diagnosed and 5.9% had known thyroid dysfunction. The prevalence of thyroid disease in the non diabetic control group was 6.6%.⁵⁹

Chubb et al in a cross-sectional study of 420 patients with type 2 diabetes mellitus found that 8.6% of patients had subclinical hypothyroidism.⁶⁴

Smithson M J in his study found that the prevalence of thyroid disease in the entire population of diabetic patients registered in the general practice was 10.8%. In the control group of non diabetics, the prevalence was 6.6%.⁶¹

D.H. Akbar et al in their study of 100 type 2 diabetics found that the prevalence of thyroid dysfunction was 16% and in control group of non diabetics, it was 7%.⁷⁶

Zdrojewicz et al in their study of 75 diabetic patients found that there was no differences in thyroid gland function between patients with type 2 diabetes mellitus and non diabetics. This study contradicts our findings.⁶²

DISTRIBUTION OF THYROID ABNORMALITIES

In the present study, 11% (11) of the patients had report suggestive of sub clinical hypothyroidism and 5% (5) of the patients had report suggestive of sub clinical hyperthyroidism. This study was similar to Abdel-Rahman et al who in their study of 908 type 2 diabetic patients found that 10.3% of patients had hypothyroidism (overt and sub clinical) and 1.7% of patients had hyperthyroidism (overt and sub clinical).⁵⁹

Smithson et al in their study of 233 diabetes mellitus patients found that 11 patients were found to have undiagnosed thyroid disease, out of which 9 were having hypothyroidism (overt and sub clinical) and 2 were having hyperthyroidism (overt and sub clinical).⁶¹

Celani MF et al in their study of 290 type 2 diabetes mellitus patients found that 91 patients(31.4%) had abnormal TSH concentrations

out of which 48.3% had subclinical hypothyroidism, 24.2% had subclinical hyperthyroidism, 23.1% had overt hypothyroidism and 4.4% had overt hyperthyroidism.⁵⁵

In the present study, diabetic patients, when compared with the control group of normal patients in Whickham Study⁷⁷ and a 20 years follow-up of Whickham survey by Vanderpump MP et al⁷⁸ shows that the prevalence of altered thyroid profile in the study group is significant ($p=0.0064$).

The presence of altered thyroid profile in diabetic patients may be due to the fact that:

In euthyroid individuals with diabetes mellitus, the serum T3 levels, basal TSH levels and TSH response to thyrotropin releasing hormone (TRH) may all be strongly influenced by the glycemic status.⁴¹

Poorly controlled diabetes may also result in impaired TSH response to TRH or loss of normal nocturnal TSH peak.⁴³ It may be related to older age of the type 2 DM patients.⁶⁴

SIGNIFICANCE OF AGE IN PATIENTS WITH ABNORMAL THYROID PROFILE

Among the patients with abnormal thyroid profile, each 45% (9/20) of patients were found to be of age 61 and more and 40 or less. 55% (11/20) were found to be of age between 41-60 years. Though there is

difference, when compared between patients with normal and abnormal thyroid profile it has no significance ($p = 0.987$)

Vondra et al in his study found that thyroid diseases in diabetic patients is 2-3 times higher than in nondiabetic subjects; it raises with age, and is strongly influenced by female gender and autoimmune diabetes. This also contradicts with our findings.⁵⁸

ANALYSIS OF SEX DISTRIBUTION IN CASES WITH ABNORMAL THYROID PROFILE

In the present study 85.7% (12/14) patients were found to be female compared to 14.3% (2/12) male in the group with abnormal thyroid profile.

Compared between patients with normal and abnormal thyroid profile this is statistically significant ($p=0.031$).

Celani MF et al, Arthur M. Michalek et al and Abdel-Rahman et al in their study found that the prevalence of thyroid dysfunction was significantly higher in the female than in the male diabetic patients.^{55,59,67}

Also Vondra et al and Cardoso et al found significant correlation between female gender and altered thyroid profile.^{58,79}

ANALYSIS OF BMI IN CASES WITH NORMAL AND ABNORMAL THYROID PROFILE

Out of 20 patients with abnormal thyroid profile, 45% (9/20) were overweight and 30% (6/20) were obese. There was no significant correlation between BMI and abnormal thyroid profile ($p > 0.05$).

Fan W et al observed in their study that obese individuals have normal levels of thyroxine(T4) and thyroid stimulating hormone(TSH) but, increased levels of triiodothyronin(T3) in a minority of subjects.⁸¹ The findings contradict with Process et al who in their study found that besides known parameters such as age and drugs, thyroid-function tests can also be altered by diabetes mellitus and obesity.⁵⁵

SUMMARY

SUMMARY

This study aimed at estimating the prevalence of thyroid dysfunction in type 2 Diabetes mellitus patients and also to find out it's correlation with various risk factors. The study sample included 100 type 2 diabetic patients presented in the outpatients department. Each patient was assessed clinically and by laboratory investigations.

Primary observations regarding thyroid profile in patients with type 2 diabetes mellitus. In the present study, 20%(20 nos) of patients with type 2 diabetes mellitus had abnormal thyroid profile.

In patients with abnormal thyroid profile(20 nos), most common abnormality was subclinical hypothyroidism(55%) followed by subclinical hyperthyroidism(25%).

Our study showed significant correlation between abnormal thyroid profile and gender, duration of diabetes and family history of diabetes.

In persons with abnormal thyroid profile, 70% were females and 30% were males. This is statistically significant. The prevalence of thyroid abnormalities is more common in females than in males.

No significant correlation was found between altered thyroid profile and age, type of treatment, SHT and BMI.

Additional observations in the study group of type 2 diabetes mellitus subjects:

In the present study, patients ranged from 35 to 79 years of age. Maximum number of patients were in the age group between 41 to 60yrs (58%).

Majority (82%) of patients were on regular treatment and 18% were on irregular treatment.

44% patients were having family history of diabetes mellitus and 56% had no family history.

Majority (80%) of the diabetic patients were overweight and obese.

CONCLUSION

CONCLUSION

- ◆ Prevalence of thyroid dysfunction is more common among type 2 diabetes mellitus patients than in general population.
- ◆ Prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus is higher in females than in males
- ◆ There is no significant correlation between age, duration of diabetes, family history of diabetes and BMI.
- ◆ Routine screening for thyroid dysfunction in type 2 diabetes mellitus patients may be justified especially in females because the progression to overt thyroid dysfunction is associated with significant morbidity including the adverse effects on glycemic control, lipid profile, bone mineral density and cardiovascular events.

LIMITATIONS

- Study population was small.
- Associated thyroid autoimmunity was not evaluated due to constraints. So it was not able to refine the spectrum of thyroid dysfunction in type 2 diabetics.
- Follow up study was not done. So the natural history of subclinical thyroid dysfunction and its effect on various parameters could not be assessed.

ANNEXURES

BIBLIOGRAPHY

BIBLIOGRAPHY

1. Peter H Bennett, William C Knowlap. Definition, diagnosis and classification of diabetes. Joslin's diabetes mellitus 14th edition, 2005: 331-337.
2. Alvin C .Powers. Diabetes mellitus. Harrison's principles of internal medicine 17th edition, 2008: 2275-2304.
3. IDF Diabetes atlas 4th edition, 2009.
4. WHO(2003), Tech. Rep. Ser., N 916.
5. WHO(2002), Health situation in the South East Asia Region 1998-2000, New Delhi.
6. International Diabetes Federation, 20th October 2009, Montreal.
7. UN. 83rd plenary meeting, 20th December 2006. 61st session; Agenda 113.
8. Donald M Barnett, Leo P. Krall. History of diabetes. Joslin's diabetes mellitus 14th edition, 2005: 1-17.
9. Porter R. The greatest benefit to mankind, a medical history of humanity. New York: WW Norton, 1997:71.
10. Schadevaldt H. The history of diabetes mellitus. In: Van Englehardt D, ed. Diabetes, its medical and cultural history. Berlin: Springer Verlag, 1987:43–100.
11. Langerhans P. Beitrage zur mikroskopischen Anatomie der Bauchspeicheldruse. Med Diss (Berlin), 1869.

12. Morrison H. Translation and introductory essay. Langerhans P. Contributions to the microscopic anatomy of the pancreas. Bull Inst Hist Med 1937;5:259–269.
13. Minkowski O. Historical development of the theory of pancreatic diabetes (introduction and translation by R. Levine). Diabetes 1989;38:1–6.
14. De Meyer J. Contribution l'ude de la pathologie du diabete pancreatique. Archive Internationale de Physiologie 1909:121–180.
15. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922;7:251–266.
16. Savage PJ, Bennion LJ, Bennett PH. Normalization of insulin and glucagon secretion in ketosis-resistant diabetes mellitus with prolonged diet therapy. J Clin Endocrinol Metab 1979;49:830–833.
17. Agner T, Damm P, Binder C. Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients. Diabetes Care 1987;10:164–169.
18. Gavin JR III, Alberti KGMM, Davidson MB, et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
19. WHO Consultation Group. Definition, diagnosis and classification of diabetes mellitus and its complications, 2nd ed. Part 1: Diagnosis and classification of diabetes mellitus WHO/NCD/NCS/99. Geneva: World Health Organisation, 1999:1–59.

20. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–2012.
21. Dabelea D, Pettitt DJ, Jones KL, et al. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am 1999;28: 709-29.
22. American Diabetes Association 2007, Criteria for the diagnosis of diabetes mellitus. Diabetes care, Volume 30, Supplement 1, anuary 2007.
23. Howard BV. Pathogenesis of diabetic dyslipidemia. Diabetes Rev 1995;3:423–432.
24. Siegel RD, Cupples A, Schaefer EJ, et al. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996;45:1267–1272.
25. Robert H. Eckel. The metabolic Syndrome. Harrison's principles of internal medicine 17th edition,2008:1509-1514.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High

Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.

27. J, Larry Jameson, Anthony P. Weetman. Disorders of thyroid gland. Harrison's principles of internal medicine 17th edition, 2008: 2224-2247.
28. Thyroid and Antithyroid drugs. Katzung Basic clinical pharmacology 10th edition, 2007: 618-634.
29. Physiological effects of thyroid hormones. William F. Ganong Review of medical physiology 22nd edition: 317-332.
30. P.Reed Lorson, F. Davies. Quantitation of serum thyroid hormone concentration. Williams textbook of Endocrinology 11th edition: 299-332.
31. Nikhil Tandon. API Text book of medicine 8th edition:1002-1010
32. Chidakel A, Mentuccia D, Celi FS: Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid 2005; 15:899-903.
33. Gregory A. Brent, P. Reed Larsen, Terry F. Davies. Hypothyroidism and thyroiditis. Williams textbook of Endocrinology 11th edition: 377-409.
34. Huber G, Staub J-J, Meier C, et al: Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87:3221-3226

35. Kvetny J, Heldgaard PE, Bladbjerg EM, et al: Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. *Clin Endocrinol (Oxf.)* 2004; 61: 232-238
36. Cappola AR, Fried LP, Arnold AM, et al: Thyroid status, cardiovascular risk, and mortality in older adults. *JAMA* 2006; 295:1033-1041.
37. F. Davies, P.Reed Lorson. Thyrotoxicosis. *Williams textbook of Endocrinology* 11th edition: 333-368.
38. Silva JE: The thermogenic effect of thyroid hormone and its clinical implications. *Ann Intern Med* 2003; 139:205-213.
39. Faber J, Galloe AM: Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *Eur JEndocrinol* 1994; 130:350-356.
40. R. Sathish,V. Mohan. Diabetes and Thyroid disease-A Review. *Int J of Diabetes in Developing countries* 2003;23; 120-123.
41. Schlienger JL, Anceau A, Chabrier G, North ML,. Stephan F. Effect of diabetic control on the level of circulating thyroid hormones. *Diabetologia*. 1982;22;486-8
42. Donckier JE. Endocrine diseases and diabetes. In: *Textbook of Diabetes mellitus*. Pickup JC, Williams G (eds), Blackwell Publishing Company, Chichester, 2003: 27.1– 27.25.

43. Coiro V, Volpi R, Marchesi C, et al. Influence of residual C-peptide secretion on nocturnal serum TSH peak in well-controlled diabetic patients. *Clin. Endocrinol.* 1997;47:305-10.
44. Kalmann R, Mourits M. Diabetes Mellitus: a risk factor in patients with Grave's orbitopathy. *Br. J. Ophthalmol.* 1999; 83: 463-465.
45. Taylor R, Muculloch A, Zeuzem S, Gray P, Clark F, Alberti G. Insulin secretion, adipocyte insulin binding and insulin sensitivity in thyrotoxicosis. *Acta Endocrinol.* 1985;109:96-103.
46. Ahren B, Lundquist I, Hedner P, Valdemassan S, Scheroten B. Glucose tolerance and insulin and C-peptide responses after various insulin secretions stimuli in hyperthyroid and hypothyroid subjects before and after treatment *diab. Res. Clin. Practice.* 1985;2:95-103.
47. Randin J, Tappy L, Scazziga B, Jequier E, Felber J. Insulin sensitivity and exogenous insulin clearance in Grave's disease. Measurements by the glucose clamp technique and continuous glucose calorimetry. *Diabetes.* 1986;35:178-81.
48. Bech K, Damsbo P, Eldrup E, et al. Beta cell function and glucose and lipid oxidation in Grave's disease. *Clin. Endocrinol.* 1996;44: 59-66.
49. Dimitriadis G, Raptis S A. Thyroid hormone excess and glucose intolerance. *Exp Clin. Endocrinol. Diabetes.* 2001; 109: S225-S239.

50. Holness M, Sugden M. Continued glucose output after refeeding contributes to glucose intolerance in thyroid disease. *Biochem. J.* 1987;247:801-4.
51. Mokuno T, Uchimura K, Hayashi R, et al. Glucose transporter concentration in hyper and hypothyroid rat livers. *J. Endocrinol.* 1999;160:285-9.
52. Haber R, Wilson C, Weinstein S, Pritsker A, Cushman S. Thyroid hormone increases the partitioning of glucose transporters to the plasma membrane in ARL 15 cells. *Amer. J. Physiol.* 1995; 269:E605-E610.
53. Dimitriadis G, Parry-Billings M, Bevan S, et al. The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats. *Eur. J. Clinical. Invest.* 1997; 27:475-83.
54. Mohn A, Di Michele S, Di Luzio R, Tumini S, Chiarelli F. The effect of sub clinical hypothyroidism on metabolic control in children and adolescents with type 1 diabetes mellitus. *Diab. Med.* 2002; 19:70-3.
55. Celani MF, Bonati ME, Stucci N. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with Type 2 diabetes mellitus. *Diabetes Res* 1994; 27: 15-25.

56. Procas S, Delgrange E, Vander Borgh TV, Jamart J, Donckier JE. Minor alterations in thyroid-function tests associated with diabetes mellitus and obesity in outpatients without known thyroid illness. *Acta Clin Belg*. 2001 Mar-Apr; 56(2):86-90.
57. Roderick E. Warren, Petros Perros, Moffat J. Nyirenda, Brian M. Frier. Serum Thyrotropin is a better predictor of future thyroid Dysfunction than Thyroid Autoantibody status in biochemically euthyroid patients with Diabetes: Implications for Screening. *Thyroid*. 2004, 14(10): 853-857.
58. Vondra K, Vrbikova J, Dyorakova K. Thyroid gland diseases in adult patients with diabetes mellitus. *Minerva Endocrinol*. 2005 Dec;30(4):217-36
59. Abdel Rahman, Nusier MK, Amari FL et al. Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan. *Saudi Med J*. 2004 Aug;25(8):1046-50.
60. Perros P, Mc Crimmon RJ, Shaw G, Frier BM, Frequency of thyroid dysfunction in diabetic patients, value of annual screening. *Diabet Med* 1995;12:622-627.
61. Smithson MJ. Screening for thyroid dysfunction in a community population of diabetic patients. *Diabet Med* 1998; 15 (2): 148-50.
62. Zdrojewicz Z, Humpich G, Januszewski A, Adamek J. The assessment of thyroid gland function in patients with non-insulin

dependent diabetes mellitus(type 2). Wiad Lek.1999;52(1-2): 35-41.

63. Parr JH. The effect of long-term metabolic control on free thyroid hormone levels in diabetics during insulin treatment. *Ann Clin Biochem.* 1987 Sep; 24 (Pt 5):466-9.
64. Chubb SA, Davis WA, Inman Z, Davis DME. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. *Clin Endocrinol (Oxf).* 2005 Apr;62(4):480-6.
65. Wild S, Rogli G, Green A. Global prevalence of diabetes estimates for the year 2000 and projection for 2030. *Diabetes Care*, 2004; 27: 1047-53.
66. Kapur A., Snehlatha C., Ramchandran A., Vijay V., Mohan V., Das A.K., Rao P.V., Yajnik C.S., Prasanna Kumar K.M., Jyotsna Nair: High prevalence of diabetes and impaired glucose tolerance in India. National Urban diabetes survey. *Diabetologia* 2001; Vol. 44: 1094 –1101.
67. Arthur M.Michalek, Martin C.Mahoney, Donald Calebaugh: Hypothyroidism and Diabetes Mellitus in an American Indian Population. *Journal of family practice* 2000 July; 49:638-640.
68. Jali MV, Mohan V, Ramchandran A, Snehlatha C and Viswanathan M; High Prevalence of diabetes in an Urban population in South India. *BMJ* Sept 1988; Vol. 297: p- 587-590.

69. Flatau E.; Trougouboff P.; Kaufman N.; Reichman N.; Luboshitzky R. Prevalence of hypothyroidism and diabetes mellitus in elderly kibbutz members. *European Journal of Epidemiology*, Volume 16, Number 1, January 2000 , pp. 43-46(4).
70. Tattersal R.B., Fojans S, Arbor A: Prevalence of Diabetes and Glucose Intolerance in offsprings of 37 conjugal Diabetic parents. *Diabetes* 1975, 24:452-462.
71. Vishwanthan M, Mohan V, Snehlatha C, Ramchandran A: High prevalence of type 2 Diabetes among the offspring of conjugal type 2 parents in India. *Diabetologia*, 1985, 28:907-910.
72. Asha A, Pradeepa R, Mohan V. Evidence for Benefits from diabetes education program. *Int J Diab Dev Countries* 2004; 24:96-102(4).
73. Kaur K, Singh MM, Kumar, Walia I. Knowledge and self-care practices of diabetics in a resettlement colony of Chandigarh. *Indian J Med Sci*. 1998;52:3417.
74. Mc Larty DG, Kitange, Chuwa LM: Prevalence of Diabetes and impaired glucose tolerance in rural Tanzania 1989, 22: 871-74.
85. Yon Gik Kim, Youngsoo Shin, Younsoo Park. Prevalence of Diabetes and impaired glucose tolerance in Yonchon country, South Lorea, *Diabetic care* 1994, 545-48.

76. D.H. Akbar, M.M.Ahmed, J. Al-Mughales. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. *ActaDiabetol*(2006).43;14-18.
77. Tunbridge WMG, Evered DC and Hall R et al; The spectrum of thyroid disease in a community. The Whickham survey. *Clin. Endocrinol(oxf)* 1977; 7: 481-93.
78. Vanderpump MP, Tunbridge WM, Frence JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty year follow up of whickham survey. *J Clin Endocrinology* 1995;43(1):55-68.
79. Cardoso C, Ohwovoriole AE, Kuku SF. J Diabetes. A study of thyroid function and prevalence of thyroid auto antibodies in an African diabetic population. *J Diabetes Complications* 1995; 9:37-41.
80. Muz Nez A, Gonzez Sarmiento E, Ergueta Mart P, Escorial Miguel C, Crespo Pinilla J, Mara n Cabello A. Thyroid function study in patients with diabetes mellitus. *An Med Interna.* 1990 Jun; 7(6):291-3.
81. Fan W, Dinulescu DM, Butler AA, et al. The central melanocortin system can directly regulate serum insulin levels. *Endocrinology* 2000;141:3072–3079

RECOMMENDATIONS

Biochemical tests of thyroid functions are readily available and relatively inexpensive. So, a baseline thyroid function test to be done in all type 2 diabetic patients at first visit especially in females.

Longitudinal studies are needed to find out the incidence of thyroid dysfunction in type 2 diabetes mellitus patients and to determine the need of regular screening for thyroid dysfunction during follow up and its cost effectiveness.

Follow up thyroid function test to be done to assess the progression of subclinical thyroid dysfunction in type 2 diabetics because of associated morbidity of overt thyroid dysfunction in these patients.

PROFORMA

**DEPARTMENT OF MEDICINE
K.A.P.VISHWANATHAM GOVT. MEDICAL COLLEGE,
TRICHY**

PROFORMA

**STUDY OF THYROID PROFILE IN TYPE 2 DIABETES
MELLITUS**

Name	:	Age/Sex:
Address	:	
Occupation	:	
Presenting Complaints	:	
Tiredness		Dry Skin
muscle cramps		Decreased sweating
Insomnia		Somnolence
Poor Appetite		Myalgia/Arthralgia
Weight Gain/Weight Loss		Breathlessness
Cold Intolerance		Swollen Limb
Constipation		Paresthesia
Change in Voice		Impaired Hearing
Menstrual Irregularities		Infertility/Abortion
Libido		Poor Memory /Difficulty in concentration
Behavioral Changes		Tremors
Palpitations		Irritability

Past history

HT/ Others :

IHD :

DIABETIC HISTORY

Duration of diabetes :

Diabetic Status :

FAMILY HISTORY

Hypothyroidism Goiter

PERSONAL HISTORY

Diet :

Menstrual History :

TREATMENT HISTORY

OAD :

Insulin :

GENERAL EXAMINATION

Height :

Weight :

BMI :

Pallor	Icterus	Xanthelasma	Madarosis
Pulse	Peripheral Pulsation		
B. P.			
Skin	: Cold/Coarse/Moist/Dry/Yellowish Discoloration		
Edema			
Facial Puffiness			
Thyroid Gland	: Normal/Enlarged		

SYSTEMIC EXAMINATION

C. V. S.	:
R. S.	:
P/A	:
C. N. S.	:

INVESTIGATIONS

Hb (gm%)	:
FBS	:
PPBS	:
B. Urea	:
Sr. Creatinine	:
ECG	:

THYROID PROFILE

FT3 :

FT4 :

TSH :

REMARK:

Signature of the guide

MASTER CHART

MASTER CHART

S. No	Name	Age/sex	Duration of diabetes (Years)	Regularity of treatment	Family history	BMI kg/m ²	FT3 rg/ml	FT4 hg/dl	TSH mIU/ml
1.	Mr. Rangasamy	38/M	1Y	Reg	YES	24.73	1.86	0.78	4.18
2.	Mrs. Moushika beevi	51/F	15Y	Irreg	YES	31.04	3.2	1.23	2.62
3.	Mrs. Nashini begum	39/F	4Y	Reg	NO	23.37	2.88	1.29	1.88
4.	Mrs. Pappa	48/F	1.5Y	Reg	NO	23.61	1.19	0.81	3.32
5.	Mrs. Dhanushkodi	50/F	2/12Y	Reg	YES	30.43	2.59	0.63	38.43
6.	Mrs. Meharunisha	47/F	3/12Y	Reg	NO	27.16	2.93	1.02	2.03
7.	Mrs. Manimegalai	53/F	5Y	Reg	YES	35.2	2.5	0.7	4.73
8.	Mr. Ismail	50/M	3Y	Reg	YES	27.63	3.65	0.97	2.45
9.	Mrs. Andal	60/F	1.5Y	Reg	YES	31.34	3.12	0.89	0.41
10.	Mrs. Parvathy	50/F	4/12Y	Reg	NO	35.55	2.42	0.79	1.95

11.	Mrs. Selvi	38/F	3/12Y	Reg	YES	28.81	2.89	1.19	3.24
12.	Mr. Prabakaran	47/M	4/12Y	Reg	NO	29.09	2	1.08	3.66
13.	Mrs. Kairunisha	37/F	2/12Y	Reg	YES	28.22	2.94	1.2	3.24
14.	Mr. Palanisamy	60/M	10Y	Irreg	NO	26.7	3.2	1.4	7.92
15.	Mrs. Elisa	60/F	3Y	Reg	NO	25.96	2.42	1.26	0.34
16.	Mr. Gopal	65/M	6Y	Irreg	NO	32	2.51	1.11	0.44
17.	Mrs. Meenambigai	42/F	6/12Y	Reg	YES	33.77	1.5	0.46	>150
18.	Mrs. Vasanthakumari	40/F	2 Y	Reg	NO	30.8	2.72	0.86	6.24
19.	Mrs. Nagalakshmi	43/F	3.5Y	Reg	YES	30.08	2.76	1.35	3.4
20.	Mrs. Tamilarasi	40/F	6.5Y	Reg	NO	25.68	3.2	1.88	0.28
21.	Mrs. Sethu	45/F	2Y	Reg	NO	30.01	3.49	1.21	1.75
22.	Mrs. Rajalakshmi	57/F	3Y	Reg	YES	28.57	2.57	0.86	5.924
23.	Mrs. Maanvizhi	46/F	4Y	Reg	NO	26.47	2.81	1.2	5.938

24.	Mr. Periyasamy	72/M	11Y	Irreg	YES	22.03	2.18	1.05	9.696
25.	Mr. Annadurai	36/M	1Y	Reg	YES	23.43	2.99	1.07	6.139
26.	Mrs. Uma mageswari	40/F	2Y	Reg	NO	25.2	3.62	1.8	<0.01
27.	Mr. Kumar	53/M	3Y	Reg	YES	25.55	2.69	0.85	9.611
28.	Mrs. Pushpa	56/F	3Y	Reg	NO	27.11	2.33	0.71	35.64
29.	Mrs. Shanmugarani	52/F	5Y	Reg	YES	25.8	2.61	1	5.671
30.	Mr. Maniyan	59/M	5Y	Reg	NO	27.68	3.15	1.1	6.434
31.	Mrs. Sunathbee	40/F	1.5Y	Irreg	YES	30.54	2.51	1.01	1.56
32.	Mrs. Velmani	45/F	10Y	Reg	NO	30.91	2.6	0.88	8.9
33.	Mr. Abdulhaleem	45/M	5Y	Reg	YES	31.34	2.4	1.02	2.45
34.	Mrs. Amsavalli	42/F	1Y	Reg	NO	30.8	2.79	0.65	9.81
35.	Mrs. Ramu	55/F	5Y	Reg	YES	30.28	2.43	0.91	1.17
36.	Mr. Gunasekaran	40/M	1Y	Irreg	NO	30.91	8.41	4.72	0.015

37.	Mr. Santhanam	42/M	1Y	Reg	YES	31.95	1.54	1.11	1.246
38.	Mrs. Nandhini	35/F	1Y	Reg	NO	24.77	1.9	1.54	2.864
39.	Mr. Ramaiya	75/M	12Y	Reg	YES	24.03	2.34	0.9	1.559
40.	Mr. Duraisamy	68/M	16Y	Irreg	YES	27.34	4.11	0.79	1.673
41.	Mrs. Jaya	40/F	1.5Y	Reg	YES	26.66	3.45	0.98	3.057
42.	Mrs. Kalyani	60/F	5Y	Reg	NO	32.23	2.43	1.45	0.505
43.	Mrs. Valli	49/F	2Y	Reg	NO	27.94	1.78	1.78	0.802
44.	Mrs. Sumathy	36/F	1Y	Reg	NO	29.09	2.67	1.43	5.173
45.	Mrs. Suryapraba	49/F	3Y	Reg	NO	26.37	3.66	1.22	1.887
46.	Mr. Ponnusamy	56/M	3Y	Reg	YES	29.29	3.76	1.04	1.52
47.	Mr. Santhanasamy	45/M	2Y	Irreg	NO	27.23	2.54	0.71	1.844
48.	Mr. Murugan	40/M	1Y	Reg	NO	29.13	1.97	0.86	0.728
49.	Mrs. Kaliammal	48/F	3Y	Reg	YES	35.2	1.76	1.76	1.651

50.	Mr. Sundarajan	64/M	7Y	Reg	NO	30.46	1.99	1.33	4.914
51.	Mr. Palanisamy	41/M	1Y	Reg	YES	30.04	2.3	1.66	1.705
52.	Mr. Ramkumar	35/M	1Y	Irreg	NO	29.38	1.89	1.8	1.247
53.	Mr. Bala	62/M	8Y	Reg	NO	25.4	1.97	1.67	2.562
54.	Mr. Veeramuthu	79/M	10Y	Irreg	YES	27.26	3.76	1.32	0.812
55.	Mrs. Selvamani	50/F	2Y	Reg	NO	26.69	2.89	0.85	1.534
56.	Mr. Senthilkumar	40/M	1.5Y	Reg	NO	26.45	2.34	0.95	3.218
57.	Mrs. Papathy	49/F	3Y	Reg	YES	27.23	2.19	1.39	2.849
58.	Mr. Abdulmalik	65/M	5Y	Irreg	NO	26.95	3.13	1.67	4.389
59.	Mrs. Lalitha	50/F	2.5Y	Reg	YES	25.1	1.88	1.55	1.658
60.	Mr. Somasundaram	50/M	2Y	Irreg	YES	23.61	1.99	1.79	1.636
61.	Mr. Arokyasamy	65/M	6.5Y	Reg	YES	27.81	2.76	0.92	3.609
62.	Mrs. Leelavathy	57/F	3.5Y	Reg	YES	29.51	2.88	1.56	1.927

63.	Mrs. Kulanthaithersa	60/F	2Y	Reg	NO	24.44	3.46	1.68	4.289
64.	Mr. Syed rasool	65/M	7Y	Reg	NO	31.44	3.87	1.76	2.79
65.	Mrs. Vaidehi	58/F	2Y	Irreg	YES	25.64	2.1	1.51	1.525
66.	Mrs. Shanmugavalli	36/F	2Y	Reg	YES	22.86	2.71	1.59	1.101
67.	Mr. Gunasekaran	60/M	6Y	Reg	NO	26.02	3.03	0.74	1.346
68.	Mr. Vetrivel	55/M	2Y	Irreg	YES	26.39	4.01	0.93	2.51
69.	Mr. Alagappan	77/M	8Y	Reg	YES	24.55	2.38	1.49	1.819
70.	Mr. Manikam	62/M	5Y	Irreg	YES	25.19	2.81	1.75	3.238
71.	Mrs. Jaya	39/F	1Y	Reg	NO	24.24	3.17	1.3	0.205
72.	Mr. Tamilarasan	50/M	2Y	Reg	NO	26.03	3.05	1.49	3.932
73.	Mr. Muthurathnam	72/M	13Y	Reg	NO	29.67	3.17	1.68	5.052
74.	Mr. Ramesh	37/M	2Y	Reg	YES	29.96	3.13	1.46	3.093
75.	Mr. Velu	56/M	6Y	Reg	NO	29.27	2.31	0.96	1.469

76.	Mrs. Kursheed	52/F	6Y	Irreg	NO	30.1	3.09	1.8	2.885
77.	Mr. Savarimuthu	66/M	5.5Y	Reg	YES	26.89	2.9	1.48	3.371
78.	Mr. Murugesan	43/M	1Y	Reg	NO	18.32	1.96	1.62	2.227
79.	Mr. Rajagopal	58/M	6Y	Reg	NO	27.18	1.81	1.04	1.993
80.	Mrs. Parveen	35/F	1Y	Reg	NO	28.93	3.79	1.02	1.361
81.	Mrs. Suganthi	37/F	1Y	Reg	NO	23.01	2.66	1.11	0.21
82.	Mrs. Meenakshi	50/F	2Y	Reg	NO	31.04	3.54	1.3	5.178
83.	Mrs. Latha	35/F	1Y	Irreg	YES	18.14	3.03	1.32	0.172
84.	Mr. Vijaykumar	53/M	2.5Y	Reg	NO	27.84	2.67	1.37	1.628
85.	Mr. Arokyasamy	62/M	7Y	Reg	NO	27.51	2.9	1.08	3.86
86.	Mr. Sankar	50/M	2Y	Reg	NO	27.14	2.77	1.69	1.785
87.	Mr. Selvaraj	48/M	5Y	Reg	NO	28.65	3.8	1.67	2.189
88.	Mrs. Mahalakshmi	60/F	6Y	Reg	YES	28.76	3.56	1.66	1.526

89.	Mr. Arokyadas	42/M	4Y	Reg	NO	29.29	2.78	1.03	4.224
90.	Mr. Velu	64/M	6.5Y	Reg	NO	26.72	2.21	1.18	1.407
91.	Mr. Kandasamy	63/M	6Y	Reg	NO	25.97	2.69	1.31	3.764
92.	Mrs. Mallika	51/F	3Y	Reg	NO	28.9	2.98	1.06	0.918
93.	Mr. Arumugam	52/M	4.5Y	Reg	YES	24.03	3.69	1.18	1.125
94.	Mr. Selvam	35/M	1Y	Reg	NO	21.63	3.23	1.37	3.58
95.	Mr. Rajendran	52/M	3Y	Irreg	NO	20.07	2.77	1.58	1.673
96.	Mrs. Senbagavalli	75/F	12Y	Reg	YES	27.97	2.18	1.77	3.899
97.	Mr. Pandurangan	56/M	6Y	Reg	NO	22.97	2.94	1.59	2.283
98.	Mr. Muthukrishnan	56/M	3Y	Reg	YES	25.1	3.22	1.03	2.407
99.	Mrs. Lakshmi	50/F	2Y	Reg	NO	25.72	1.94	1.64	1.851
100.	Mr. Senthil	35/M	1.5Y	Reg	YES	19.1	2.53	1.72	1.49